Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis
- PMID: 25563886
- DOI: 10.1097/SLA.0000000000001109
Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis
Abstract
Objective: To investigate the individual and combined prognostic value of HIF1α, SLC2A1, and vascular endothelial growth factor A (VEGFA) in a multi-institutional cohort of patients with resected colorectal cancer liver metastasis (CRCLM).
Background: In the majority of patients with CRCLM, resection seems not to be curative, despite its curative intent. Overexpression of hypoxia-inducible factor 1α (HIF1α), glucose transporter 1 (SLC2A1; also known as GLUT1), and VEGFA has been associated with tumor progression and poor prognosis of patients with colorectal cancer (CRC).
Methods: Tissue microarrays were generated using CRCLM and patient-matched primary CRC from patients who underwent CRCLM resection between 1990 and 2010. Prognostic value of HIF1α, SLC2A1, and VEGFA was determined by immunohistochemistry. A 500-fold cross-validated hazard rate ratio (HRRav) for overall survival was calculated.
Results: HIF1α, SLC2A1, and VEGFA expression could be evaluated in 328, 350, and 335 patients, respectively. High SLC2A1 expression was associated with good prognosis (HRRav, 0.67; P (HRR >1) < 0.01) and high VEGFA expression to poor prognosis (HRRav, 1.84; P (HRR < 1) = 0.02), also after multivariate analysis including established clinicopathological prognostic variables (HRRav, 0.67; P (HRR > 1) < 0.01 and HRRav, 1.50; P (HRR < 1) = 0.02, respectively). SLC2A1 showed prognostic value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic value of VEGFA expression was mainly observed in patients not treated with systemic therapy (P < 0.01). Prognosis was especially poor in patients with both low SLC2A1 and high VEGFA expression (P < 0.01). HIF1α expression was not associated with survival.
Conclusions: SLC2A1 and VEGFA expression are prognostic molecular biomarkers for patients with CRCLM with added value to established clinicopathological variables.
Similar articles
-
A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.Oncotarget. 2016 Jan 12;7(2):2123-34. doi: 10.18632/oncotarget.6188. Oncotarget. 2016. PMID: 26497206 Free PMC article.
-
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.Br J Cancer. 2014 Aug 12;111(4):749-55. doi: 10.1038/bjc.2014.354. Epub 2014 Jul 1. Br J Cancer. 2014. PMID: 24983372 Free PMC article.
-
Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S527-36. doi: 10.1245/s10434-013-2945-2. Epub 2013 Jun 9. Ann Surg Oncol. 2013. PMID: 23748663
-
Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma.Int J Mol Sci. 2018 Oct 3;19(10):3014. doi: 10.3390/ijms19103014. Int J Mol Sci. 2018. PMID: 30282914 Free PMC article. Review.
-
Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.Front Cell Dev Biol. 2021 Apr 12;9:612774. doi: 10.3389/fcell.2021.612774. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33912554 Free PMC article. Review.
Cited by
-
The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.Mol Med. 2022 Jul 14;28(1):78. doi: 10.1186/s10020-022-00504-6. Mol Med. 2022. PMID: 35836112 Free PMC article.
-
miR‑1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.Oncol Rep. 2018 Aug;40(2):589-598. doi: 10.3892/or.2018.6463. Epub 2018 May 24. Oncol Rep. 2018. PMID: 29845255 Free PMC article.
-
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.Oncotarget. 2017 Jun 13;8(24):38193-38213. doi: 10.18632/oncotarget.16942. Oncotarget. 2017. PMID: 28445144 Free PMC article.
-
Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin.Front Oncol. 2021 Jun 24;11:682665. doi: 10.3389/fonc.2021.682665. eCollection 2021. Front Oncol. 2021. PMID: 34249728 Free PMC article.
-
Circ_0030998 promotes tumor proliferation and angiogenesis by sponging miR-567 to regulate VEGFA in colorectal cancer.Cell Death Discov. 2021 Jun 24;7(1):160. doi: 10.1038/s41420-021-00544-7. Cell Death Discov. 2021. PMID: 34226531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous